Safety and Immunogenicity of Ad26-vectored HIV Vaccine with Mosaic Immunogens and a Novel Mosaic Envelope Protein in HIV-uninfected Adults: A Phase 1/2a Study.

Daniel J StiehDan H BarouchChristy ComeauxMichal SarneckiKathryn E StephensonStephen R WalshSheetal SawantJack HeptinstallGeorgia D TomarasJames G KublinM Juliana McElrathKristen W CohenStephen C De RosaGalit AlterGuido FerrariDavid MontefioriPhilipp MannSteven NijsKatleen CallewaertPaul A GoepfertSrilatha EdupugantiEtienne KaritaMichael S SeamanLawrence CoreyLindsey R BadenMaria G PauHanneke SchuitemakerFrank Tomaka

Published in: The Journal of infectious diseases (2022)

Adding mosaic gp140 to the clade C regimen increased and broadened the elicited immune response without compromising safety or clade C responses.

Keyphrases

hiv infected
antiretroviral therapy
hiv positive
hiv testing
immune response
human immunodeficiency virus
hepatitis c virus
hiv aids
men who have sex with men
south africa
toll like receptor
dendritic cells
binding protein